

Dr. D.P. Thomas  
Department of Health and Social Security  
Medicines Division  
Finsbury Square House  
33-37a Finsbury Square  
London E.C. 2

WdAM/amg

4th January 1973

Dear Dr. Thomas,

I enclose comments on the product licence applications for Hemofil and Kryobulin.

I have little to add to your own summaries and conclusions. I think both will prove to be acceptable but Seriological Products Ltd have failed to supply the evidence in the form required and should be asked to fill the gaps.

In my opinion the use of these two products should be restricted initially to a small number of selected haemophilia centres so that their value can be examined critically. Thereafter, assuming the claims are substantiated which seems probable, I think their sale should continue to be limited to haemophilia centres and hospitals. They should not be available merely on prescription. There is much to be said for DHSS dealing with this material in the same way as it dealt with immunoglobulin purchased from commercial sources. The argument is even stronger in the case of anti-haemophilic globulin because of its very high cost.

As this aspect of these applications is not a matter for the Subcommittee on Biologicals I am sending a copy of this letter to Dr. Waiter, Mr. Gidden and Mr. Walters but not, of course, copies of my comments on the licence applications.

I am very sorry I cannot come to the meeting of the Subcommittee on 10th January 1973 and ask you to give my apologies to the Chairman.

The copies of the applications will be sent back under separate cover.

Yours sincerely,

GRO-C

W.d'A. Maycock, C.B.E., M.D.

c.c. Dr. Waiter  
Mr. Gidden  
Mr. Walters